HS in Practice: Case-Based Approaches to Advancing Care

Hidradenitis suppurativa often goes undiagnosed for years while patients quietly absorb pain, odor, and isolation. The panel examines why recognizing these signals early changes everything that follows.

Three FDA-approved biologics now intercept the inflammatory cascade at different points, yet Dr. Laura Bush argues a calm exam can understate real disease burden. The panel discusses when history should outweigh appearance.

A 29-year-old with years of axillary and groin disease illustrates how psychosocial toll, not just visible lesions, should guide the decision to escalate beyond conventional HS therapy.

Adalimumab, secukinumab, and bimekizumab each carry distinct trial populations and response rates. The panel reviews years of efficacy and safety data behind today's approved HS biologics.

Black box warnings, screening requirements, and real-world experience all shape which biologic fits a given patient. The panel applies these safety considerations directly to the first case.

Setting realistic timelines and reading quality of life matter as much as counting lesions. The panel also flags a common pitfall: mistaking healing pigment changes for active disease.